Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

• Olema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors.

• The early readout highlighted tumor shrinkage and a clean safety profile in patients with difficult-to-treat cancers.

• More detailed results are scheduled to be presented at the 2026 ASCO Annual Meeting.

For investors tracking oncology pipelines, this update puts more attention on Olema Pharmaceuticals, which is developing targeted cancer therapies. OP-3136 is described as a first-in-class oral KAT6 inhibitor, adding a differentiated mechanism to the broader field of precision oncology drugs and combination treatment approaches.

Looking ahead, readers will likely focus on how upcoming ASCO data shape Olema's plans for OP-3136 as both a stand-alone treatment and part of combination regimens. The Phase 1 results also mark a notable R&D milestone for NasdaqGS:OLMA, providing the market with a clearer view of Olema's expansion beyond its existing programs.

Stay updated on the most important news stories for Olema Pharmaceuticals by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Olema Pharmaceuticals.

📰 Beyond the headline: 3 risks and 2 things going right for Olema Pharmaceuticals that every investor should see.

Quick Assessment

• ✅ Price vs Analyst Target: At US$13.68 versus an analyst consensus of US$41.82, the stock trades about 67% below the target range.

• ✅ Simply Wall St Valuation: Simply Wall St currently flags the stock as trading 92.6% below its estimated fair value.

• ❌ Recent Momentum: The share price is down 11.9% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Olema Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Olema Pharmaceuticals's Fair Value .

Key Considerations

• 📊 Early OP-3136 data with anti-tumor activity and a clean safety profile supports the case that Olema is building a broader oncology pipeline around targeted therapies.

• 📊 Watch the 2026 ASCO presentation for durability of responses, dose selection, and any signals in specific tumor types that could guide later stage studies.

• ⚠️ The company currently reports minimal revenue and is loss making, so future trial costs, funding needs, and shareholder dilution remain central risks.